Brexpiprazole for Bipolar Depression


The purpose of this study is to determine if the investigational drug brexpiprazole can reduce depressive symptoms severity in patients with bipolar disorder.


An 8-week, non-randomized, open-label study of brexpiprazole study of 20 persons with bipolar disorder. The study is open to English-speaking outpatient men and women age 18-65 years old, who are currently on mood stabilizer therapy or are willing to start within 14 days prior to starting the study.

Participants must not have a severe or life-threatening medical condition (e.g., hepatic cirrhosis), have a high risk for suicide, or be considered part of a vulnerable population (e.g. pregnant, cognitively impaired, or incarcerated). We do, however, encourage all patients to call the researchers to be screened for the study criteria.


Our recent research findings have shown that brexpiprazole could be a promising medication to treat depressive mood symptoms.

Frequently Asked Questions

Q: What medication will I be given?

A: Enrolled participants will receive one medication: Brexpiprazole

Q: What will my visits consist of?

A: Each visit will consist of structured assessments and laboratory tests administered by a research assistant and psychiatrist. 

Q: Is compensation available for participation in the study?

A: Yes, patients will be compensated for their time and efforts contributed for the study.

Q: Is transportation available for the study appointments?

A: Yes. DART passes will be made available to study participants who need transportation assistance.